FX.co ★ Kura Gains 17% Over Positive Preliminary Clinical Data From Phase 1 Trial Of Ziftomenib

Shares of Kura Oncology, Inc. (KURA) experienced a surge of 15 percent on Tuesday morning, following the company's announcement of encouraging preliminary data from the phase 1 trial of Ziftomenib. Presently, the stock has risen by 15.75 percent to reach $21.58, a significant leap from the previous close at $18.60, with trading volumes of 8,141,727 shares. Over the past 52 weeks, Kura's shares have been traded within a range of $7.41 to $22.92 on the Nasdaq.

As per the data collected up until January 11, all newly diagnosed patients who underwent treatment with Ziftomenib and cytarabine/daunorubicin attained a complete remission along with a full count recovery.